×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
TRVI – trevi therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
TRVI
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/17
02:18 pm
trvi
Trevi Therapeutics: Late-Stage Transition Meets Execution Risk [Seeking Alpha]
Low
Report
Trevi Therapeutics: Late-Stage Transition Meets Execution Risk [Seeking Alpha]
4/17
01:43 pm
trvi
Trevi Therapeutics (TRVI) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $19.00 price target on the stock.
Low
Report
Trevi Therapeutics (TRVI) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $19.00 price target on the stock.
4/16
10:42 pm
trvi
Trevi Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock
High
Report
Trevi Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock
4/16
04:14 pm
trvi
Trevi Therapeutics launches $150M public stock offering [Seeking Alpha]
High
Report
Trevi Therapeutics launches $150M public stock offering [Seeking Alpha]
4/16
04:08 pm
trvi
Trevi Therapeutics Announces Proposed Public Offering of Common Stock
High
Report
Trevi Therapeutics Announces Proposed Public Offering of Common Stock
4/5
06:22 am
trvi
A Look At Trevi Therapeutics (TRVI) Valuation After FDA End Of Phase 2 Milestone For IPF Chronic Cough [Yahoo! Finance]
Medium
Report
A Look At Trevi Therapeutics (TRVI) Valuation After FDA End Of Phase 2 Milestone For IPF Chronic Cough [Yahoo! Finance]
4/1
07:48 am
trvi
Trevi Therapeutics to Participate in Upcoming Events [TheStreet.com]
Low
Report
Trevi Therapeutics to Participate in Upcoming Events [TheStreet.com]
4/1
07:30 am
trvi
Trevi Therapeutics to Participate in Upcoming Events
Low
Report
Trevi Therapeutics to Participate in Upcoming Events
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/17
04:18 pm
trvi
Form 424B5 Trevi Therapeutics, Inc.
Low
Report
Form 424B5 Trevi Therapeutics, Inc.
4/17
08:07 am
trvi
Form 8-K Trevi Therapeutics, Inc. For: Apr 16
High
Report
Form 8-K Trevi Therapeutics, Inc. For: Apr 16
4/16
04:16 pm
trvi
Form 424B5 Trevi Therapeutics, Inc.
High
Report
Form 424B5 Trevi Therapeutics, Inc.
4/10
04:33 pm
trvi
Form PRE 14A Trevi Therapeutics, Inc. For: Apr 10
Low
Report
Form PRE 14A Trevi Therapeutics, Inc. For: Apr 10
3/27
01:32 pm
trvi
Form SCHEDULE 13G/A Trevi Therapeutics, Inc. Filed by: VANGUARD GROUP INC
Low
Report
Form SCHEDULE 13G/A Trevi Therapeutics, Inc. Filed by: VANGUARD GROUP INC
3/17
04:09 pm
trvi
Form 10-K Trevi Therapeutics, Inc. For: Dec 31
Medium
Report
Form 10-K Trevi Therapeutics, Inc. For: Dec 31
3/17
04:07 pm
trvi
Form 8-K Trevi Therapeutics, Inc. For: Mar 17
Medium
Report
Form 8-K Trevi Therapeutics, Inc. For: Mar 17
3/9
04:35 pm
trvi
Form 8-K Trevi Therapeutics, Inc. For: Mar 09
Low
Report
Form 8-K Trevi Therapeutics, Inc. For: Mar 09
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/31
Trevi Therapeutics Inc (NASDAQ: TRVI) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.50 price target on the stock.
67.9%
3/16 TREVI THERAPEUTICS ANNOUNCES FOURTH QUARTER AND YEAR END 2019 FINANCIAL RESULTS AND CORPORATE UPDATE 48.3%
6/18 Trevi Therapeutics to Present at BMO Prescriptions for Success Healthcare Conference 12.7%
5/13 Form 3 Trevi Therapeutics, Inc. For: May 07 Filed by: OSHEA WILLIAM J 11.5%
3/16 Trevi Therapeutics up 57% on advancement of key programs [Seeking Alpha] 10.3%
4/13 Form 4 Trevi Therapeutics, Inc. For: Apr 03 Filed by: Behbahani Ali 9.9%
2/25 Trevi Therapeutics Inc (NASDAQ: TRVI) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 8.6%
1/15 Trevi Therapeutics Inc (NASDAQ: TRVI) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 7.9%
11/14 Form 8-K Trevi Therapeutics, Inc. For: Nov 14 7.9%
8/21 Trevi Therapeutics Inc (NASDAQ: TRVI) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 7.6%
3/16 TREVI THERAPEUTICS ANNOUNCES FOURTH QUARTER AND YEAR END 2019 FINANCIAL RESULTS AND CORPORATE UPDATE 48.3%
6/18 Trevi Therapeutics to Present at BMO Prescriptions for Success Healthcare Conference 12.7%
5/13 Form 3 Trevi Therapeutics, Inc. For: May 07 Filed by: OSHEA WILLIAM J 11.5%
3/16 Trevi Therapeutics up 57% on advancement of key programs [Seeking Alpha] 10.3%
4/13 Form 4 Trevi Therapeutics, Inc. For: Apr 03 Filed by: Behbahani Ali 9.9%
2/25 Trevi Therapeutics Inc (NASDAQ: TRVI) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 8.6%
1/15 Trevi Therapeutics Inc (NASDAQ: TRVI) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 7.9%
11/14 Form 8-K Trevi Therapeutics, Inc. For: Nov 14 7.9%
8/21 Trevi Therapeutics Inc (NASDAQ: TRVI) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 7.6%
TOP News Decliners
5/7
Form S-1/A Trevi Therapeutics, Inc.
-16.9%
10/10 Trevi Therapeutics Inc (NASDAQ: TRVI) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -9.8%
3/11 Trevi Therapeutics Inc (NASDAQ: TRVI) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -8.8%
8/12 Trevi Therapeutics Announces Second Quarter 2019 Financial Results and Recent Business Developments -7.1%
1/31 Form SC 13G Trevi Therapeutics, Inc. Filed by: Lundbeckfond Invest A/S -6.2%
2/13 Form SC 13G Trevi Therapeutics, Inc. Filed by: TPG Group Holdings (SBS) Advisors, Inc. -6.2%
9/19 Trevi Therapeutics Inc (NASDAQ: TRVI) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -4.9%
2/20 Trevi Therapeutics to Present at SVB Leerink Healthcare Conference -4.0%
7/2 Form 8-K Trevi Therapeutics, Inc. For: Jun 28 -4.0%
6/25 Trevi Therapeutics (TRVI) Investor Presentation - Slideshow [Seeking Alpha] -3.8%
10/10 Trevi Therapeutics Inc (NASDAQ: TRVI) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -9.8%
3/11 Trevi Therapeutics Inc (NASDAQ: TRVI) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -8.8%
8/12 Trevi Therapeutics Announces Second Quarter 2019 Financial Results and Recent Business Developments -7.1%
1/31 Form SC 13G Trevi Therapeutics, Inc. Filed by: Lundbeckfond Invest A/S -6.2%
2/13 Form SC 13G Trevi Therapeutics, Inc. Filed by: TPG Group Holdings (SBS) Advisors, Inc. -6.2%
9/19 Trevi Therapeutics Inc (NASDAQ: TRVI) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -4.9%
2/20 Trevi Therapeutics to Present at SVB Leerink Healthcare Conference -4.0%
7/2 Form 8-K Trevi Therapeutics, Inc. For: Jun 28 -4.0%
6/25 Trevi Therapeutics (TRVI) Investor Presentation - Slideshow [Seeking Alpha] -3.8%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: